D&D Pharmatech Amends Pfizer Obesity Drug R&D Contract Amount Up 2.5 Times, Negligible Impact on Stock

D&D Pharmatech filed a correction disclosure increasing the contract amount for its obesity drug formulation development R&D service agreement with Pfizer from KRW 1.83 billion to KRW 2.53 billion.
The increase of approximately KRW 694 million is only 0.02% of the market cap of KRW 3.86 trillion, representing negligible financial impact.
The counterparty remains Pfizer, a top-tier global pharmaceutical company with high credibility, and the adjustment reflects expanded research scope without changes to other terms.
[AI Summary]This amendment increases the contract value but is immaterial relative to market capitalization, thus no meaningful impact on shareholder value. Continued collaboration with Pfizer is a positive signal for long-term technology validation, but near-term stock price effect is limited.